Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 3
1994 1
1995 3
1996 2
1997 3
1998 1
1999 5
2000 3
2001 6
2002 8
2003 8
2004 7
2005 16
2006 14
2007 11
2008 15
2009 7
2010 10
2011 16
2012 16
2013 8
2014 13
2015 14
2016 9
2017 15
2018 5
2019 2
2020 4
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Results by year

Filters applied: . Clear all
Page 1
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.
Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J. Razavi P, et al. Among authors: hudis c. Cancer Cell. 2018 Sep 10;34(3):427-438.e6. doi: 10.1016/j.ccell.2018.08.008. Cancer Cell. 2018. PMID: 30205045 Free PMC article.
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Citron ML, et al. Among authors: hudis c. J Clin Oncol. 2003 Apr 15;21(8):1431-9. doi: 10.1200/JCO.2003.09.081. Epub 2003 Feb 13. J Clin Oncol. 2003. PMID: 12668651 Clinical Trial.
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. Toy W, et al. Among authors: hudis c. Nat Genet. 2013 Dec;45(12):1439-45. doi: 10.1038/ng.2822. Epub 2013 Nov 3. Nat Genet. 2013. PMID: 24185512 Free PMC article.
RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.
McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, Sneige N, Moughan J, Shah A, Germain I, Hartford AC, Rashtian A, Walker EM, Yuen A, Strom EA, Wilcox JL, Vallow LA, Small W Jr, Pu AT, Kerlin K, White J. McCormick B, et al. Among authors: hudis c. J Clin Oncol. 2015 Mar 1;33(7):709-15. doi: 10.1200/JCO.2014.57.9029. Epub 2015 Jan 20. J Clin Oncol. 2015. PMID: 25605856 Free PMC article. Clinical Trial.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF; Breast Cancer Intergroup of North America. Albain KS, et al. Among authors: hudis c. Lancet Oncol. 2010 Jan;11(1):55-65. doi: 10.1016/S1470-2045(09)70314-6. Epub 2009 Dec 10. Lancet Oncol. 2010. PMID: 20005174 Free PMC article.
Breast cancer.
Carlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis C, Jahanzeb M, Ljung BM, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC; National Comprehensive Cancer Network. Carlson RW, et al. Among authors: hudis c. J Natl Compr Canc Netw. 2005 May;3(3):238-89. doi: 10.6004/jnccn.2005.0015. J Natl Compr Canc Netw. 2005. PMID: 16002000 No abstract available.
Epoetin alfa: to give or not to give.
Dang C, Hudis C, Norton L. Dang C, et al. Among authors: hudis c. J Natl Cancer Inst. 2013 Jul 17;105(14):1001-3. doi: 10.1093/jnci/djt172. Epub 2013 Jul 16. J Natl Cancer Inst. 2013. PMID: 23860203 No abstract available.
The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention.
Delahanty LM, Wadden TA, Goodwin PJ, Alfano CM, Thomson CA, Irwin ML, Neuhouser ML, Crane TE, Frank E, Spears PA, Gillis BP, Hershman DL, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hudis C, Winer EP, A Carey L, Partridge AH, Ligibel JA. Delahanty LM, et al. Among authors: hudis c. Obesity (Silver Spring). 2022 Jan;30(1):28-38. doi: 10.1002/oby.23287. Obesity (Silver Spring). 2022. PMID: 34932888 Free PMC article. Review.
199 results